Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Breast Cancer treatment details. Biologic therapy. Chemotherapy. Karolinska Institutet and University Hospital, Stockholm, Sweden

Survival: 24.8 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: Sweden
City/State/Province: Stockholm
Hospital: Karolinska Institutet and University Hospital
Journal: Link
Date: 2/2012

This phase III study involved women with advanced breast cancer who were separated into two separate treatment groups. Group A consisted of 296 patients with a median age of 54 years. Group B had 297 patients with a median age of 56 years.

Patients in group A were treated with the biologic therapy agent sunitinib (a tyrosine kinase inhibitor that targets blood supply to the tumor) and the chemotherapy agent docetaxel.

Group B was treated with docetaxel alone.

In group A there were 6 treatment-related deaths, the causes of which included heart attack and pulmonary embolism. Fatigue and hand-foot skin reaction were also reported.

The most severe treatment-related toxicities in group B were grade 4 nerve disorders and fatigue.

The median overall survival for group A was 24.8 months. For group B, the median overall survival was 25.5 months.

Several of the authors were employed by or received funding from pharmaceutical companies, including Pfizer, the makers of sunitinib.

Correspondence: Dr. Jonas Bergh; email:

E-mail to a Friend Email Physician More Information